Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). An intermediate clinical phenotype caused by substitution of valine for glycine at position 137 of arylsulfatase B

• Published in: The Journal of biological chemistry 1991-11, Vol.266 (32), p.21386-21391
• Main Authors: WICKER, G, PRILL, V, BROOKS, D, GIBSON, G, HOPWOOD, J, VON FIGURA, K, PETERS, C
• Format: Article
• Language: English
• Subjects: Alleles; Amino Acid Sequence; Base Sequence; Biological and medical sciences; Blotting, Western; Cell Line; Chondro-4-Sulfatase - genetics; Chondro-4-Sulfatase - metabolism; Cloning, Molecular; Errors of metabolism; Glycine; Humans; Kinetics; Medical sciences; Metabolic diseases; Miscellaneous hereditary metabolic disorders; Molecular Sequence Data; mucopolysaccharidosis; Mucopolysaccharidosis VI - enzymology; Mucopolysaccharidosis VI - genetics; Mutagenesis, Site-Directed; Mutation; N-acetylgalactosamine-4-sulfatase; Oligodeoxyribonucleotides; Phenotype; Polymerase Chain Reaction - methods; Recombinant Proteins; Restriction Mapping; RNA - genetics; RNA - isolation & purification; Valine
• ISSN: 0021-9258; 1083-351X
• DOI: 10.1016/S0021-9258(18)54649-4

The Maroteaux-Lamy syndrome (mucopolysaccharidosis type VI) is a lysosomal storage disease with autosomal recessive inheritance caused by deficiency of the enzyme arylsulfatase B. Severe, intermediate, and mild forms of the disease have been described. The molecular correlate of the clinical heterogeneity is not known at present. To identify the molecular defect in a patient with the intermediate form of the disease, arylsulfatase B mRNA from his fibroblasts was reverse-transcribed, amplified by the polymerase chain reaction, and subcloned. Three point mutations were detected by DNA sequence analysis, two of which, a silent A to G transition at nucleotide 1191 and a G to A transition at nucleotide 1126 resulting in a methionine for valine 376 substitution, were polymorphisms. A G to T transversion at nucleotide 410 causing a valine for glycine 137 substitution (G137V) was identified as the mutation underlying the Maroteaux-Lamy phenotype of the patient, who was homozygous for the allele. The kinetic parameters of the mutant arylsulfatase B enzyme toward a radiolabeled trisaccharide substrate were normal excluding an alteration of the active site. The G137V mutation did not affect the synthesis but severely reduced the stability of the arylsulfatase B precursor. While the wild type precursor is converted by limited proteolysis in late endosomes or lysosomes to a mature form, the majority of the mutant precursor was degraded presumably in a compartment proximal to the trans Golgi network and only a small amount escaped to the lysosomes accounting for the low residual enzyme activity in fibroblasts of a patient with the juvenile form of the disease.